30 results about "Partial antigen" patented technology

The invention relates to a microorganism as a carrier of nucleotide sequences coding for antigens and protein toxins comprising the following components: (I) at least one nucleotide sequence coding for at least one complete or partial antigen of at least one wild-type or mutated protein; and (II) at least one nucleotide sequence coding for at least one protein toxin and / or at least one protein toxin subunit; and (III) a) at least one nucleotide sequence coding for at least one transport system which enables the expression of the expression products of component (I) and component (II) on the outer surface of the microorganism and / or enables the secretion of the expression products of component (I) and component (II); and / or coding for at least one signal sequence which enables the secretion of the expression products of component (I) and component (II); and / or (III) b) optionally, at least one nucleotide sequence coding for at least one protein for lysing the microorganism in the cytosol of mammalian cells and for intracellularly releasing plasmids or expression vectors, which are contained in the lysed microorganism; and (IV) at least one nucleotide sequence for at least one activation sequence for the expression of one or more of components (I) to (III), wherein said activation sequence can be activated in the microorganism and / or is tissue cell-specific, tumor cell-specific, macrophage-specific, dendrite-specific, lymphocyte-specific, function-specific or non-cell-specific”; wherein any of components (I) to (IV) can be present either once or several times and either identical or different. Also disclosed are a process of manufacturing thereof, corresponding plasmids or expression vectors and uses of the microorganism as a medicament.

CTnI synthetic polypeptide antibody, its production and use are disclosed. The process is carried out by synthesizing polypeptide by 98-110 amino-acid at N end of amino-acid sequence RQLHARVDKVDEE, taking it as partial antigen to connect with protein carrier, preparing artificial immunogen, immunizing for animal, inducing organism effectively, generating immune response to obtain antibody, specific combined reacting cTnI synthetic polypeptide antibody with natural myoepicardial protein I molecule and coating cellulose nitrate film by the antibody, and reducing by tri-sodium citrate to obtain the final product. It's fast and has better sensitivity and specificity, and it can be used for acute myocardial infarction early diagnostic technology.

Disclosed herein is an immunoassay method for detecting the detection target antigen in an analyte through extraction with an extraction agent. The method is characterized in that the detection is performed in the presence of a cyclic oligosaccharide. The method is also characterized in the use of an immunochromatography kit for detecting gram-positive bacteria in an analyte, and that is configured from an analyte dilution solution, a sample dropping part, an antigen extracting part, a labeling substance retaining part, an immunochromatography medium having a detection part, and an absorption part, and in which an organic acid is retained in the antigen extracting part. The immunochrornatography kit contains a cyclic oligosaccharide and a nitrite compound by containing at least one of a cyclic oligosaccharide, a nitrite compound, and a mixture thereof in the analyte dilution solution and / or the sample dropping part.

The invention relates to the technical field of biomedical tissue engineering, in particular to a novel bone tissue engineering scaffold and a preparation method thereof. The bone scaffold comprises abone material and an exosome-loaded fibrin gel compound, the bone material is provided with holes, and the gel compound is distributed in the holes. The invention researches a bone material which ishighly similar to a natural bone matrix and has osteogenesis and vascularization activities. The porous decellularized tissue engineering scaffold is closer to a normal bone, has good biomechanical properties, is suitable for bone defect repair of a load bearing area, and maximally retains inherent components of the scaffold. According to the method, cell components with most antigens in tissues can be effectively removed, the immunological rejection reaction of grafts is reduced, the approximate morphological structure of the tissues can be maintained, and most tissue matrix components and bioactive factors are retained.

The invention discloses a fenvalerate artificial partial antigen, the molecular structure is in the right, and n=1-5. The invention also provides the method for synthesizing fenvalerate artificial partial antigen, and the application of the product as raw material of antigen system for animal immunization.

The invention relates to a vaccine composition comprising an immunizing dose of a canine parvovirus antigen and an immunizing dose of another antigen, and relates to a kit comprising an effective amount of the canine parvovirus antigen and an effective amount of another antigen. The composition and the kit can be effectively used for preparation of medicines preventing and / or treating canine parvovirus infection related diseases. The composition and the kit can effectively prevent present epidemic canine parvovirus wild strains, and synergistic effects with some antigens in other antigens aregenerated, thus further improving immunization effects of a combined vaccine.

The invention provides moderately hydrolyzed formula powder for inducing the oral immune tolerance. The powder is prepared from, by weight, 3-15% of moderately hydrolyzed whey protein powder, 2-10% ofmoderately hydrolyzed casein, 60-75% of glucose syrup, 10-25% of mixed vegetable oil, 0.1-0.5% of docosahexoenoic acid oil, 0.1-0.5% of arachidonic acid oil, 0.5-10% of caprylic / capric triglyceride,0.1-0.5% of anhydrous cream, 0.1-0.6% of multi-vitamin and 0.4-2.2% of composite minerals. The formula powder has the advantages that the aminogram is balanced, sensitization is reduced, partial antigens are retained, and the formula powder has oral immune tolerance; the fatty acid spectrum is balanced, and the palatability is enhanced by adding short-chain fat.

The invention relates to an in vitro method of evaluating the immunological activity of a vaccine preparation in the form of a mixture of a molecular antigen and a carrier, wherein the mixture comprises a liquid phase and a solid phase, to which at least a part of the antigen is attached, the method comprising the steps of i) subjecting the vaccine to one or more measurements selected from the group consisting of: 1) the immunological activity of the mixture, 2) the immunological activity of antigen in the liquid phase, 3) the immunological activity of antigen in the solid phase, 4) the immunological activity of antigen in the liquid phase upon a treatment of the mixture to displace the antigen from the solid phase, and 5) the immunoligical activity of antigen in the solid phase upon a treatment of the mixture to displace the antigen from the solid phase, wherein the immunological activity measurement is selected from the group consisting of antibody binding capacity using an immunoassay employing an antigen-specific antibody bound to an antibody solid phase, b) ability to activate effector cells and c) potential for inducing anaphylaxis; and ii) using the measurement results.

The invention discloses a fenvalerate artificial antigen, with the molecular structural formula is as formulaó±, n=1-5, employing formula ó� as partial antigen, covalent coupling with protein for synthesis; the combination ratio between the partial antige and protein is 5:1-100:1. The invention also discloses the monoclonal or polyclonal immune globulin G which is got from immunizating mouse or rabbit by the above said fenvalerate artificial antigen and can occur specific immunological reaction with fenvalerate, the said fenvalerate specific antibody can be used to check the residual quantity of fenvalerate in sample. The invention also discloses a detecting agent box of direct and indirect competeing enzyme and immunoadsorption for fenvalerate residual analysis. The got antibody is used to detect fenvalerate by ELISA method, with the lowest detecting limit being 4.0í‚1.5 ug / l (0.004ppm), and the detecting sensitivity is high.

It is an object of the present invention to a method whereby a humoral immune response is induced more efficiently in producing an antibody against an antigen protein by gene immunization. A fusion gene composed of a gene encoding the full-length of a part of the antigen protein or a gene encoding a chaperonin subunit or a chaperonin subunit linkage linked thereto is administered to express the fusion gene in the animal, thereby inducing a humoral immune response to an antigen protein by administering. An example of the chaperonin includes Escherichia coli GroEL. There is also provided with a composition for immunization, a method for producing an antibody, a method for producing a hybridoma, and a method for producing a monoclonal antibody.

The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (FcγRIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.

Formulations and preparations having immune memory enhanced properties are disclosed that provide for enhancing immune response against a tumor growth, cancer, infectious agent, bacteria, virus or other infectious or non-infectious agent. The vaccine formulation includes an immune memory invoking component, such as an antigen of an infectious agent, virus (e.g., Rabies), bacteria, prion, neo-antigen or other moiety antigen, and a targeted antigen (e.g., a harvested tumor tissue (B-cell, T-cell, epitopes)). The vaccine formulation / preparations may comprise a target infectious agent protein / peptide component (such as a SARS-Cov-2 spike protein epitope) mixed with, or fused to (or otherwise conjugated) an immune-memory associated viral antigen (such as Rabies, polio, or other peptide / protein antigen or peptide or fragment thereof).

The invention features methods of identifying and validating affinity reagents, such as antibodies. The methods of the invention generally involve screening an antibody library by, for example, phage display on bacteria (e.g., E. coli) to identify particular antibody clones capable of binding a desired target polypeptide. Clones identified in this way can then be validated using yeast 2-hybrid. In some instances, antibodies identified by their capacity to binding a partial antigen can be validated by their capacity to bind to the full-length antigen. Validated clones can be further screened by additional rounds of phage display and / or yeast 2-hybrid. Between each round, additional variants of particular antibody clones can be generated and screened to identify variants that demonstrate higher binding affinity to the target of interest.

The invention provides a preparation method of a viral vaccine. The preparation method comprises the following steps: providing a coding sequence of a full-length or partial antigen peptide or protein of at least one virus, dividing the coding region of the full-length or partial antigen peptide or protein into one or more partially overlapped nucleic acid sequences, and connecting the one or more partially overlapped nucleic acid sequences in series to form a nucleic acid vaccine fragment. After the nucleic acid vaccine prepared by using the preparation method of the viral vaccine is injected into animals and human bodies, small-fragment antigen peptide vaccines are formed through in-vivo cell treatment, so serious side effects possibly caused by full-length protein vaccines can be effectively avoided, but the immunogenicity of antigen peptides or proteins can be maintained, and therefore, virus infection can be effectively antagonized. Meanwhile, a small-fragment antigen peptide component can be rapidly and correspondingly adjusted according to the mutation of the S protein of the new coronavirus, so the nucleic acid vaccine can also be effective to new coronavirus mutant strains. The invention also provides a pharmaceutical composition obtained through the preparation method of the viral vaccine.

The present invention provides a conjugate comprising: i) at least one first specific binding molecule which binds CD40, wherein said first specific binding molecule is an agonist of CD40; and ii) at least one second specific binding molecule which binds a tag moiety, wherein said tag moiety is not a cancer antigen, wherein said first specific binding molecule and second specific binding molecule are antigen-binding proteins comprising an antigen-binding domain of an antibody and are covalently linked. The conjugate can be combined with a tag construct comprising: i) a tag moiety which is not a cancer antigen; and ii) an antigen, being a cancer antigen or an antigen derived from a pathogen; wherein said antigen is a polypeptide and said tag moiety is covalently linked to said antigen, for use in therapy, to stimulate an immune response by a subject against the antigen in question.

The invention provides a strategy for site specific covalent modification of antibodies using a specialized targeting covalent heterobivalent ligand (cHBL), and corresponding design for a covalent heterobivalent inhibitor (cHBI) that can be used to prevent Immunoglobulin E (IgE) mediated allergic reactions triggered by drug molecules, according to one embodiment. These molecules contain four important components: (1) an IgE antigen binding site (ABS) ligand that can be a mimotope for the allergen protein, a small molecule, or a peptidomimetic, (2) an appropriate linker, which can be any flexible or rigid chemical linker, providing spacing between the ABS binder and the other moieties, (3) a nucleotide binding site (NBS) ligand, and (4) a reactive moiety to form a covalent link with an amino acid side chain of target IgE antibodies.